VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
COLL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
COLLCollegium Pharmaceutical, Inc.
$25.55$841M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCOLLCash Flow

Collegium Pharmaceutical, Inc. (COLL) Cash Flow Statement

13Y historyFree accessUpdated daily

Operating cash flow of $86.5M in 2026Q3 against net income of $21.8M, with capital expenditures under 0.4% of revenue, suggests strong cash conversion, although free cash flow margins swung between -5.8% and 59.6% across periods, pointing to working-capital timing effects.

Income StatementBalance SheetCash FlowRatios

COLL Cash Flow Statement

Annual statement

COLL Cash Flow Statement

Collegium Pharmaceutical, Inc. (COLL) cash flow statement — 13-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash from Operations338.02M329.32M204.98M274.75M124.23M103.56M93.94M27.78M169.39M-67.02M-75.05M-21.57M-17.95M-16.53M
Operating CF Margin %-42.19%32.46%48.48%26.78%37.4%30.3%9.36%60.41%-235.35%-4386.5%---
Operating CF Growth %57.25%60.66%-25.39%121.16%19.96%10.23%238.13%-83.6%352.75%10.71%-248%-20.17%-8.57%-
Net Income38.17M62.87M69.19M48.16M-25M71.52M26.75M-22.72M-39.13M-74.86M-94.18M-27.25M-17.92M-16.2M
Depreciation & Amortization232.82M226.07M169.16M149.26M138.94M68.92M61.55M15.48M110.91M594K655K171K187K169K
Stock-Based Compensation47.56M41.91M32.4M27.14M22.87M24.25M21.91M16.53M13.78M7.95M5.79M2.21M22K62K
Deferred Taxes-44.67M-25.66M-26.81M-2.15M-8.39M-78.04M0001.84M00079K
Other Non-Cash Items15.02M20.37M16.02M30.62M8.52M3.42M9.03M-5.59M19.28M-34K-34K-28K-20K-9K
Working Capital Changes49.12M3.76M-54.98M21.73M-12.71M13.49M-25.3M24.08M64.55M-2.5M12.71M3.34M-219K-634K
Change in Receivables-18.25M17.2M-4.41M3.59M-21.78M-22.52M-10.37M4.99M-68.23M-7.84M-2.13M000
Change in Inventory11.19M-5.35M13.93M14.17M48.27M-2.3M-8.27M-1.83M219K-497K-1.32M000
Change in Payables356K6.72M-11.28M5.06M-707K-5.83M3.77M06.46M-3.42M5.57M1.3M990K-822K
Cash from Investing-521.31M-63.53M-287.76M-70.81M-573.69M-1.94M-373.77M-6.44M-24.35M-990K-2.98M-362K-8K-206K
Capital Expenditures-1.73M-1.74M-1.65M-461K-1.62M-1.94M-5.55M-6.44M-24.35M-990K-2.98M-362K-8K-206K
CapEx % of Revenue0.21%0.22%0.26%0.08%0.35%0.7%1.79%2.17%8.69%3.48%173.99%---
Acquisitions-655.4M0-267.54M0-572.07M000000000
Investments--------------
Other Investing000000-368.23M0-18.88M0-2.5M000
Cash from Financing178M-110.25M-60.6M-140.18M436.72M-89.3M286.47M2.04M-117.2M33.48M135.56M115.99M12.04M12.35M
Debt Issued (Net)251.8M-70.38M7.52M-65.92M442.68M-50M281.39M010.02M-2.67M-2.67M-1.34M11.97M395K
Equity Issued (Net)-45.87M-19.46M-60.02M-75M-14.06M-47.86M0-822K-30K34.34M137.34M116.84M011.96M
Dividends Paid0000000000-24.57M-24.57M00
Share Repurchases-50M-25.1M-60.02M-75M-14.06M-47.86M0-822K-560K00000
Other Financing-27.94M-20.4M-8.1M740K8.1M8.56M5.08M2.86M-127.19M1.81M885K25.07M72K1K
Net Change in Cash-5.29M155.55M-143.38M63.76M-12.74M12.31M6.64M23.39M27.84M-34.53M57.53M94.06M-5.92M-4.38M
Free Cash Flow336.29M327.58M203.33M274.29M122.61M101.61M-279.83M21.34M145.04M-68.01M-78.03M-21.93M-17.95M-16.74M
FCF Margin %41.25%41.97%32.2%48.4%26.43%36.7%-90.26%7.19%51.72%-238.83%-4560.49%---
FCF Growth %16.24%61.11%-25.87%123.71%20.66%136.31%-1410.99%-85.28%313.26%12.84%-255.83%-22.13%-7.28%-
FCF per Share8.608.255.036.563.622.48-7.960.644.40-2.25-3.22-1.62-2.40-2.24
FCF Conversion (FCF/Net Income)8.81x5.24x2.96x5.71x-4.97x1.45x3.51x-1.22x-4.33x0.90x0.80x0.79x1.00x1.02x
Interest Paid72.47M68.76M62.43M73.26M52.53M17.61M18.97M709K000000
Taxes Paid50.16M60.04M52.09M24.2M10.4M3M483K0000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Leverage limits revenue shortfall tolerance

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Flow Far Exceeds Volatile Earnings

According to reported quarterly figures, COLL generated operating cash flow of $86.5M in 2026Q3 against net income of just $21.8M, while 2026Q2 net loss of $15.1M still produced $71.3M of operating cash flow, pointing to heavy non-cash charges.

The gap between net income and operating cash flow is the dominant signal in this dataset, with OCF/NI ratios swinging from -4.74 to 3.98 and from 22.92 in 2025Q1 to 2.49 in 2025Q3. This pattern suggests reported earnings are dominated by amortization of acquired intangibles and accrual timing rather than by the cash economics of the business. Investors should monitor whether the cash generation proves durable once working capital and rebate accrual swings normalize, since the quarterly noise makes earnings a poor standalone proxy for cash power.

Free Cash Flow Margins Swing With Working Capital

Based on reported figures, COLL's free cash flow margin ranged from -5.8% in 2024Q3 to 59.6% in 2025Q4, with a 2026Q3 margin of 39.9%, indicating that quarterly FCF is driven more by working capital timing than by a steady operating trend.

Capital expenditure is negligible, running below 0.5% of revenue in every period, so FCF tracks operating cash flow almost one-for-one. The sharp working capital reversals, including a $64.0M outflow in 2024Q3 and a $33.8M inflow in 2025Q4, appear to explain most of the margin volatility. The trailing trend is encouraging, but a single-quarter read is not sufficient to establish a sustainable margin level.

Capital Intensity Is Negligible Across Periods

As reported in financial statements, COLL's capital expenditures stayed between $65K and $798K per quarter, equal to roughly 0.0% to 0.4% of revenue, implying an asset-light cash profile that depends on amortization rather than reinvestment.

Depreciation and amortization of roughly $55M to $57M per quarter far exceeds capital spending, which indicates that the non-cash charge is driven almost entirely by acquired intangible assets rather than productive equipment. This makes the D&A add-back the largest reconciling item between net income and cash flow. Investors should recognize that low capex flatters free cash flow, while the amortization burden reflects the price paid for past acquisitions.

Buybacks Intermittent, Acquisitions Dominate Outflows

Based on reported figures, COLL deployed $655.4M into acquisitions in 2026Q2 while paying no dividends in any period and making buybacks of $25.0M to $50.0M in only four of ten quarters, suggesting cash is directed toward portfolio expansion rather than shareholder returns.

The 2026Q2 acquisition outflow exceeds that quarter's operating cash flow by roughly nine times, implying the purchase was financed through debt or balance sheet resources rather than internal cash generation. Given the reported debt-to-equity ratio of 3.12, this sequencing warrants further investigation into how the acquisition was funded. Repurchases appear opportunistic rather than systematic, consistent with management prioritizing deleveraging and portfolio diversification.

Cumulative Cash Outpaces Reported Earnings

Across the ten reported quarters, COLL's cumulative operating cash flow of roughly $636M compares with cumulative net income of roughly $117M, indicating that accrual-based earnings have materially understated cash generation over this window.

The cumulative gap of more than five times between operating cash flow and net income is unusually wide and suggests that non-cash amortization and accrual dynamics dominate reported profitability. This divergence means that GAAP earnings may understate the economic cash contribution of the franchise. Investors should view the gap as a reason to examine the sustainability of the amortization base rather than as proof of earnings quality.

Cash Strength May Mask Leverage Exposure

Based on reported figures, COLL's strong quarterly operating cash flow coexists with a debt-to-equity ratio of 3.12 and a net margin of 8.1%, suggesting that cash generation may overstate financial flexibility if revenue growth stalls further.

The cash flow profile is dominated by non-cash amortization add-backs, so the headline OCF figures may not translate fully into discretionary capacity once debt service and acquisition commitments are considered. The 2026Q2 acquisition outflow of $655.4M raises questions about the balance sheet cost of that transaction that the provided data does not fully resolve. Investors should monitor whether operating cash flow remains durable after normalizing for working capital swings and whether opioid-related production quota constraints affect the cash base.

COLL — Frequently Asked Questions

Quick answers to the most common questions about buying COLL stock.

How much cash does Collegium Pharmaceutical, Inc. (COLL) generate from operations?

Collegium Pharmaceutical, Inc. (COLL) generated $329.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Collegium Pharmaceutical, Inc.'s free cash flow?

Collegium Pharmaceutical, Inc. (COLL) generated $327.6M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Collegium Pharmaceutical, Inc.'s capital expenditure (CapEx)?

Collegium Pharmaceutical, Inc. (COLL) spent $1.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Collegium Pharmaceutical, Inc. distribute cash to shareholders?

In 2025, Collegium Pharmaceutical, Inc. (COLL) spent $25.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.